Linked Life Data

21059173

Source:http://linkedlifedata.com/resource/pubmed/id/21059173

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
2011-2-28
pubmed:abstractText
Inhibitors of the epidermal growth factor receptor (EGFR) are increasingly used in the treatment of various entities of malignant tumors. Patients treated with EGFR inhibitors very likely develop cutaneous side effects. The development of a papulopustular, follicular exanthema during the first weeks of therapy correlates with therapeutic benefit. However, this exanthema and other cutaneous side effects can impair the quality of life of the patient and might limit the therapy with the EGFR inhibitor. For an optimal therapeutic benefit and quality of life an adequate management of cutaneous side effects is necessary. A panel of German dermatologists developed on the basis of personal experience and current literature consensus recommendations for the management of cutaneous side effects of EGFR inhibitors.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Mar
pubmed:issn
1610-0387
pubmed:author
pubmed:copyrightInfo
© The Authors • Journal compilation © Blackwell Verlag GmbH, Berlin.
pubmed:issnType
Electronic
pubmed:volume
9
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
195-203
pubmed:meshHeading
pubmed:year
2011
pubmed:articleTitle
Management of cutaneous side effects of EGFR inhibitors: recommendations from a German expert panel for the primary treating physician.
pubmed:affiliation
Department of Dermatology, Allergy and Venereology, Skin Cancer Center, Hannover Medical School, Germany. gutzmer.ralf@mh-hannover.de
pubmed:publicationType
Journal Article